HHS to Launch Campaign Promoting Wearable Devices

June 26, 2025

Reading Time : 2 min

On June 24, 2025, in a hearing before the U.S. House of Representatives Committee on Energy and Commerce, the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. revealed that his department plans to soon launch an advertising campaign encouraging Americans to use wearable health devices. The campaign is set to be “one of the biggest advertising campaigns in HHS history.”

As described by Secretary Kennedy, wearables enable individuals to take responsibility over their health and make informed decisions: “People can take control over their own health. . . They can see what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it. And they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives,” Secretary Kennedy said.

Secretary Kennedy went on to state that he has observed the positive impact of wearables (like glucose meters) for weight loss and diabetes management. He noted that the wearables were cost-effective—contrasting the expense of a wearable with the cost of a drug such as Ozempic—and said that the department was “exploring ways of making sure that those costs can be paid for.”

“We think that wearables are a key to the MAHA agenda—Making America Healthy Again, and . . . my vision is that every American is wearing a wearable within four years,” added Secretary Kennedy.

This announcement reflects the growing role of digital and wearable health tools in U.S. public health strategy. However, current law draws a significant distinction between wearables used only for “wellness” and wearables that are intended for use in health care decision-making. The latter are generally regulated by the Food and Drug Administration (FDA) as medical devices (or, in some cases, a certain software function available through a wearable is regulated as a medical device). Typically, medical devices need FDA clearance or approval to be covered by federal health programs. Wearable devices also raise data protection and privacy concerns, as they collect large volumes of personal and sensitive health data, which may be shared by third party apps and services. Connectivity and interoperability will also be important considerations, to the extent the objective is for consumers to be able to share this data with their providers. One of the core impediments to leveraging health metric data from wearables has been the lack of consistent approaches to incorporate such data into a patient’s health care records and treatment.

Nevertheless, as the Secretary’s comments before the Energy and Commerce Committee and the House Ways and Means Committee hearing on digital health this week underscore, digital health continues to be an active area of interest for policy-makers that resonates with the MAHA agenda.

Share This Insight

Previous Entries

Eye on FDA

June 10, 2026

On June 2, 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance on how drug and device companies may communicate health care economic information (HCEI) with payors (e.g., health insurance companies), formulary committees (e.g., pharmacy and therapeutics committees) and similar entities. The guidance, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers, is now open for comment.

...

Read More

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

Eye on FDA

May 14, 2026

As medical chatbots proliferate, a new Pennsylvania lawsuit highlights a developing trend of states leading health artificial intelligence (AI) enforcement efforts, while the Food and Drug Administration (FDA) appears to be on the sidelines.

...

Read More

Eye on FDA

May 13, 2026

On May 12, 2026, the U.S. Food and Drug Administration (FDA) announced a major milestone in its approach to post-market oversight of chemicals in the food supply, finalizing a new proactive food chemical safety post-market assessment program and releasing two foundational papers: the “Enhanced Systematic Process for Post-Market Assessment of Chemicals in Food” and the “Tool for the Prioritization of Food Chemicals for Post-Market Assessment.”

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.